Distinguish between legitimate trade remedies (anti-dumping and countervailing duties) and unilateral tariffs. How should India respond to allegations of 'structural excess capacity'?
New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →In this answer
Trade remedies are exceptions allowed under WTO rules. A country can use them to offset unfair trade only after it proves harm. Unilateral tariffs skip that test. The difference now matters directly to India. The USTR has put a 10% Section 301 "forced-labour" duty on Indian goods and is investigating India for "structural excess capacity" [1].
Trade remedies versus unilateral tariffs
| Basis | Anti-dumping / countervailing duties | Unilateral tariffs (e.g., Section 301) |
|---|---|---|
| Legal source | WTO Anti-Dumping Agreement; SCM Agreement | Domestic law of the importing country |
| Trigger | Proven dumping or subsidy, plus material injury and a causal link [2][3] | An executive finding about a whole country's practices [1] |
| Scope | Specific products and exporters | Country-wide |
| Due process | Investigation, hearings, judicial review, five-year sunset [3] | No WTO injury test |
| Legality | Permitted within the WTO | DS543 (2020): breached GATT Art. I:1 (MFN) and Art. II (bound rates); the Art. XX(a) public-morals defence failed for lack of product-level evidence [4] |
- Enforcement gap: the U.S. appealed the DS543 ruling to a non-functional Appellate Body, so the ruling remains on paper only [5].
India's response to the excess-capacity allegation
- Rebut with evidence: At the Milwaukee G20, Goyal denied that India has structural excess capacity [1]. India should back this with sector-wise data showing that its capacity serves domestic demand. That applies DS543's evidence test to the U.S. itself [4].
- Practise what it demands: India says it has banned imports made with forced labour [1]. It should publish that ban in full, with verifiable traceability.
- Use the rule-based route: Tackle genuinely subsidised imports through DGTR anti-dumping and countervailing duty investigations [6]. This shows the WTO route works.
- Multilateral push: In the G20 talks on "updating MFN" [1], India should insist on non-discrimination and evidence standards. It should also press for restoring the Appellate Body [5].
- Bilateral pragmatism: Conclude the interim tranche of the India–US BTA [1], but do not legitimise blanket country-wide tariffs.
Allegation → Firm/sector data → DGTR AD/CVD on real dumping
→ WTO/G20 evidence norm → BTA without conceding principle
India's evidence-led response chain
Trade remedies target proven harm product by product, while unilateral tariffs punish whole countries on assumption. India should answer excess-capacity charges with data, transparency and active use of its own WTO-consistent remedies, while also negotiating with the U.S. This defends a rules-based, non-discriminatory trading order consistent with SDG 17.10, while protecting India's export interests.
Sources
- 1‘India has no excess capacity, bans forced-labour imports’ — The Hindu, 3 Oct 202610% Section 301 duty; excess-capacity probe; Goyal's denial at the Milwaukee G20; forced-labour import ban; MFN session; Goyal–Greer BTA talks
- 2WTO — Technical information on anti-dumpingdumping, material injury and causal-link requirements
- 3WTO — Agreement on Subsidies and Countervailing Measures overviewconditions for countervailing duties, procedures, five-year sunset
- 4WTO — DS543: United States — Tariff Measures on Certain Goods from Chinabreaches of GATT Art. I:1 and II; Art. XX(a) defence rejected for lack of evidence
- 5WTO — United States files appeal in DS543 (26 Oct 2020)U.S. appeal; no Appellate Body division available
- 6Directorate General of Trade Remedies, Government of IndiaIndia's trade-defence authority for anti-dumping and countervailing duty investigations